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OBJECTIVES: The primary objectives of this study were to estimate the average costs 
during the initial phase of care (year of diagnosis) among West Virginia (WV)-Medicare 
beneficiaries with breast cancer (BC) and compare it with the national estimates from 
the Surveillance, Epidemiology, End Results (SEER)-Medicare database using a linear 
decomposition technique. METHODS: A retrospective observational study was con-
ducted where the study cohorts consisted of elderly women age > 66 with incident 
BC between 2003 and 2006 in WV-Medicare and SEER-Medicare. Total costs were the 
actual medical payments for all services derived from Medicare files. Generalized 
linear regressions with log link and gamma distribution were performed. Blinder-
Oaxaca decomposition was conducted to examine the extent to which predisposing, 
enabling, need-related, healthcare use and external healthcare environmental factors 
contributed to the differences in the average costs. RESULTS: Total average costs for 
WV-Medicare cohort during the initial phase of care were lower ($19,875) as compared 
to the SEER-Medicare cohort ($22,881), a difference of $3,006. After adjusting for other 
factors, the difference was $549 and remained significant. Only 16% of the difference 
in the average costs between the two cohorts were explained by the independent 
variables included in the model. Enabling resources (6.85%), healthcare use (7.53%) 
explained most of the differences in costs. CONCLUSIONS: Total average costs of BC 
care were lower in a rural state compared to the national estimates. The differences 
in the costs were not explained by the patient-level factors included in the model.
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OBJECTIVES: Patient care burden to health professionals (HPs) and health care 
institutions for many disorders, including agitation in schizophrenia or bipolar I 
disorder, may not be fully captured through claims data and/or medical records. 
The study objective was to assess this burden, specifically for agitated patients with 
schizophrenia and bipolar I disorder who visit emergency departments or psychiatric 
emergency service units. METHODS: This study consists of one-on-one qualitative 
telephone interviews followed by a web-based survey. Interviews are conducted with 
10 emergency setting-based HPs (physicians, nurses, aides, ED/hospital administra-
tors, and social workers). Interviews follow a semi-structured guide with specific 
probes/prompts to capture the intangible impacts that drive indirect and direct costs 
of care. The guide includes general open-ended questions and specific questions on 
specific areas of impact, including physical, psychological, and emotional impacts 
on the HP, as well as impacts on job performance and satisfaction. The interview 
findings inform a web-based survey (administered to a similar mix of 200 treating 
HPs) which includes multiple choice questions, rating questions, ranking exercises, 
and open-ended questions. The survey collects data such as characteristics of HPs, 
burden of treating patients including use of restraints, isolation, boarding, length of 
stay, staff abuse and injury, and direct costs. RESULTS: The results from the on-going 
interviews and web survey of the indirect burden of treating these patients with 
agitation will be reported. CONCLUSIONS: This interview and survey methodology 
comprehensively assesses the full burden of treating agitation in schizophrenia or 
bipolar I disorder patients from the point of view of various HPs. This study will help 
bridge the gap on the indirect burden of treating patients with agitation, and can be 
used to complement direct burden of care data. This methodology can be applied 
to other disease areas to comprehensively assess the burden of patient treatment.
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OBJECTIVES: The objective of this retrospective database analysis was to examine 
the most common reasons for hospitalization and the associated burden of these 
hospitalizations among children in the United States. METHODS: Data from the 2012 
Healthcare Cost and Utilization Project’s (HCUP) Kids’ Inpatient Database (KID) were 
assessed for this analysis. The top-10 most common primary discharge diagnoses 
(ICD-9-CM) were obtained for children aged 1-4, 5-9, and 10-14 years. The length of 
stay (LOS) and costs for each of these admissions were reported. Costs were esti-
mated based on charges and hospital specific cost-to-charge ratios. RESULTS: The 
most common primary discharge diagnoses were: children 1-4 years (N= 481,859), 
pneumonia (N= 41,716) and acute asthma exacerbation (N= 27,453); children 5-9 years 
(N= 321,535), pneumonia (N= 20,240) and acute asthma exacerbation (N= 18,147); and 
children 10-14 (N= 359,000), years acute appendicitis (N= 18,487) and affective psy-
choses (N= 13,221). Across all age groups, pneumonia, asthma, and chemotherapy 
administration were included in the top-10 most common diagnoses. For children 1-4 
years, chemotherapy administration had the greatest burden (mean LOS= 5.0 days, 
mean costs= $12,438; LOS range: 1.4 croup-2.6 pneumonia; cost range: $2,629 croup-
$5,164 acute bronchiolitis). For children 5-9 years, affective psychoses had the longest 
LOS (mean LOS= 8.1 days; range: 1.2 fractured humerus-4.8 acute appendicitis) and 
acute appendicitis had the greatest cost (mean cost= $12,104; range: $3,204 dehy-
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OBJECTIVES: This analysis evaluated the impact of non-medical switching (switch-
ing for a reason that is not medically related such as due to costs) from adali-
mumab (ADA) to another injectable biologic (certolizumab, golimumab, etanercept, 
or ustekinumab) on healthcare costs in patients with rheumatoid arthritis, psoriasis, 
psoriatic arthritis, ankylosing spondylitis, or Crohn’s disease following a formu-
lary management change by large national payor. METHODS: Medically stable 
adult patients with ≥ 90 days continuous ADA use were identified in OptumInsight 
database (07/01/2012-06/30/2013). Patients who subsequently switched to another 
biologic (index date) following a payer formulary change and for no apparent medi-
cal reason between 01/01/2013-06/30/2013 were defined as non-medical switchers. 
Patients who remained on ADA therapy during this period were defined as main-
tainers and their index dates were chosen randomly. Patients with hospitaliza-
tions, emergency department (ED) visits, or substantial increases in ADA dose 6 
months pre-index (baseline) were excluded to ensure medical stability. Outcomes 
included all-cause and indication-related medical (hospitalizations, ED visits, and 
outpatient visits) and total (medical and pharmacy) costs. T-tests and multivariate 
regression analyses were used to compare cohorts in costs incurred during the 6 
months post-index (follow-up) and in costs difference from baseline to follow-
up. RESULTS: Mean age was 46 and 48 years, respectively, for maintainers (n= 2,693) 
and switchers (n= 985). Switchers incurred significantly higher all-cause medical 
costs ($4,557 vs $3,310; P= .0011) and total costs ($21,996 vs $17,379, P< .0001) during 
follow-up vs maintainers. Differences from baseline to follow-up were significantly 
greater for non-medical switchers compared to maintainers in all-cause medical 
costs ($1,476, P< .0001) and total costs ($6,355, P< .0001). Adjusted regression analyses 
and indication-specific results yielded consistent findings. CONCLUSIONS: These 
real-world analyses of patients stabilized on ADA demonstrated that maintaining 
therapy with ADA was associated with significantly less healthcare expenditures 
compared to switching to another anti-TNF for a non-medical reason.
PHS27
increaSeD HealtHcare utilization aSSociateD witH obeSity
Hoshen M.B., Balicer R.
Clalit Health Services, Tel Aviv, Israel
OBJECTIVES: The obesity pandemic is driving an increase in healthcare utilization. 
However the specific breakdown of increased morbidity and associated usage requires 
linked primary care, chronic disease and hospitalization registries. Clalit Health 
Services (CHS), with its comprehensive stable database of over 4 million members, 
provides a strong base for comparing morbidity and health care utilization between 
obese and non-obese patients, thus laying the groundwork for informed health 
care policy. METHODS: We selected two random samples, 10,000 obese (BMI> 30 1/
Jan/2011) patients and 10,000 not-overweight (BMI< = 25) from the CHS database aged 
25-74, matching CHS population age standard. We linked both datasets to the chronic 
disease registry, identifying the following diagnoses: diabetes, ischemic heart disease 
(IHD), congestive heart failure (CHF), hypertension (HTN), s/p cerebral vascular acci-
dent (CVA), chronic renal failure (CRF), and rheumatoid arthritis (RA). We compared 
disease prevalence, hospital admission rates and total cost for the groups. RESULTS: 
The prevalence of all chronic disease The greatest effect was seen for diabetes 
(RR= 3.39 CI 3.15-3.65), CHF (2.23 1.79-2.78), and HTN (2.34 2.22-2.46) but also for IHD, 
CVA , CRF and RA (1.77, 1.69, 2 and 1.37 respectively). Risk of hospitalization over 
three years was increased (1.34 1.28-1.42) and, on average, there were 58% increase in 
hospitalizations and 303% overall increased cost of healthcare compared to non-obese 
patients. CONCLUSIONS: The presence of obesity increases risk of severe comorbidi-
ties within the general population. Obesity increases risk of any hospitalization and 
both total cost and total hospital admissions among patients. Our findings suggest 
the need for intensive proactive health care policy to prevent and remedy obesity to 
prevent the financial collapse of over-stretched health organizations, and indicate the 
potential for cost-effectiveness of interventions, whether behavioral, pharmaceutical, 
or surgical, or combinations thereof.
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OBJECTIVES: This study analyzes the costs of hospital care to children with TBI before 
and after a pediatric neurocritical care center (PNCC) implementation. A previous 
study1 with this sample showed improved clinical outcomes. METHODS: This retro-
spective cohort study includes 63 patients in the pre-PNCC group, and 59 post-PNCC 
patients. We merged demographic and clinical data with cost data from the hospital 
finance office for the same patient hospitalization. Outcome variables included total 
cost percentage ((direct + overhead)/median total cost pre-PNCC*100%), and overall 
length of stay (LOS) and PICU LOS. Mann-Whitney U’s, chi-squares, and multiple linear 
regression were utilized. RESULTS: Gender, race, injury mechanism, age at admis-
sion, Glasgow Coma Score, and PRISM III score were similar in the pre and post-PNCC 
groups (p> 0.05 for all). While PICU length of stay (LOS) increased post-PNCC (median 
(IQR) pre: 11 (5-15) v. post: 14 (7-22), p = 0.02), the overall hospital LOS did not change 
(pre: 32 (14-55) v. post 37 (17-58), p = 0.42. Total cost percentage increased from a 
median(IQR) of 100% (61-181%) to 143% (95-218%), p = 0.04. After adjusting for covari-
ates, total costs percentage was still significant post-PNCC compared to pre-PNCC 
(b(se) = 16.2(5.4), p = 0.003). LOS and PICU LOS were also positively related to total costs 
(b(se) = 2.6(0.1) and 2.6 (0.4) respectively, p < 0.0001 for both). CONCLUSIONS: After 
adjusting for PICU LOS, PNCC implementation remained associated with an increase 
in total cost. One would need to look outside of the initial hospitalization to determine 
if PNCC is cost effective given the improved clinical outcomes. 1 Pineda et al. Effect 
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the study period. Controls were selected based on a propensity score methodology 
ensuring exactly the same baseline lung disease distribution between the 2 groups 
and no medical claim for PH across the entire study period. RESULTS: A total of 2,236 
cases met study criteria. On average, cases were significantly (p< 0.01) younger (67 vs. 
71), more females (64% vs 58%) and higher comorbid burden (2.8 vs 2.09) compared 
to controls. After adjusting for all baseline characteristics cases had significantly 
higher (p< 0.001) inpatient admissions (5.0 vs 2.4), physician office visits (16.5 vs 
12.5), emergency room visits (0.7 vs 0.5), pharmacy claims (67 vs 54). This translated 
into higher expenditures among cases ($42,914) vs controls ($16,745) at per patient 
per year level. CONCLUSIONS: Using health plan data this study showed that Group 
3-PH poses a significant economic burden to payers.
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OBJECTIVES: To estimate the direct medical costs of severe acute respiratory infec-
tion (SARI) in children and adults from three Central American countries whit a 
bottom-up costing approach. METHODS: The costs of inpatients treatment were 
estimated through the retrospective bottom-up costing in a randomized sample of 
clinical records from SARI patients treated in teaching tertiary hospitals during 2009 
- 2011 period. Activities incurred per patient were registered and a setting-specific 
cost per activity was acquired. Average cost per patient in the group of children and 
elderly adults was estimated for each country. In Nicaragua, only the pediatric popu-
lation was included. Costs were expressed in local currency (2011), American dollars, 
and international dollars (2005) for country comparison. RESULTS: The care cost per 
case in children in Guatemala was the cheaper (I$971.95) compared to Nicaragua 
(I$1,431.96) and Honduras (I$1,761.29). In adults, the treatment cost for Guatemala 
was the more expensive: I$4,065.00 vs. I$2,707.91 in Honduras. CONCLUSIONS: 
Bottom-up costing of SARI cases allowed the mean estimates per treated case that 
could have external validity for the target population diagnosed in hospitals with 
similar epidemiological profiles and level of complexity for the study countries. This 
information is very relevant for the decision-making.
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OBJECTIVES: To investigate racial disparities in the incidence of skeletal-related 
events (SREs) and healthcare utilization costs associated with SREs among older 
African American (AA) and non-Hispanic White (NHW) men with advanced prostate 
cancer (PCa). METHODS: We identified men aged 66 or older, diagnosed with stage 
IV metastatic PCa between 2000 and 2007 from the SEER-Medicare dataset. Three 
mutually exclusive SRE categories were created for pathologic fracture (PF), spinal 
cord compression (SCC), and bone surgery (BS). Multivariable logistic regression 
models were used to assess the relationship between SREs and race, controlling 
for other demographic, clinical, and treatment characteristics. The annual unad-
justed post-SRE healthcare utilization costs included total monthly costs in the 
12-month post-period relative to the first SRE. Difference-in-difference estimates 
were derived in a propensity score matched sample to obtain annual adjusted SRE-
specific costs. We estimated unadjusted post-SRE and adjusted SRE-specific cost 
differences between AA and NHW men. RESULTS: Application of inclusion criteria 
resulted in 6,455 metastatic PCa patients with 1,035 AA and 5,420 NHW men. A 
higher proportion of NHWs (16%) experienced SREs compared to AAs (13%) (p< 0.01). 
The likelihood of experiencing SREs among AAs was lower than in NHWs after 
adjusting for individual characteristics (OR:0.81,95%CI:0.68-0.96,p= 0.02), specifi-
cally due to the lower likelihood PF and BS events among AA men. The unadjusted 
post-SRE costs among AAs were US$12,962 (95%CI:US$3,995-US$21,930;p< 0.01) 
higher compared to NHW men. However, the adjusted SRE-specific cost differ-
ences between AA and NHW men were not statistically significant. The adjusted 
SRE-specific costs were US$35,725 (95%CI:US$22,190-US$49,260) among AAs, and 
US$25,896 (95%CI:US$21,669-US$30,123) among NHWs. SRE-specific costs varied 
by SRE type, with BS costing more than PF and SCC events. CONCLUSIONS: Even 
though AA men were less likely to experience SREs than NHWs, the observed trend 
towards higher costs in advanced PCa care among AA men highlight the need for 
further research with larger, racially diverse samples.
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OBJECTIVES: Colorectal cancer (CRC) is the third most common cancer in both 
male and female in the world. Therefore, CRC causes the high economic burden 
for both patients and society. Understanding the cost of CRC is necessary to con-
duct the relevant healthcare policies, especially in Vietnam. This is also the aim of 
this study. METHODS: A decision tree model was built to analyze the cost of each 
stage based on the National Comprehensive Cancer Network Guideline in 2013. The 
average cost of CRC was evaluated by using the following formula: COI = DC + IC. 
In which: COI - cost of illness, DC- direct cost, IC- indirect cost . The analysis was 
dration-$12,100 chemotherapy administration). For children 10-14 years, affective 
psychoses had the longest LOS (mean LOS= 7.5 days; range: 1.6 acute appendicitis-4.5 
chemotherapy administration), and chemotherapy administration had the greatest 
cost (mean cost= $13,295; range: $3,790 asthma with acute exacerbation-$11,999 acute 
appendicitis). CONCLUSIONS: Children in the US are hospitalized for a variety of 
reasons, with respiratory illnesses (i.e., pneumonia, asthma, and bronchiolitis) being 
common in all age groups. The LOS associated with the most common reasons for 
hospitalization is typically short with mean costs not exceeding $14,000.
PHS33
Direct meDical coSt of comPlicationS in PatientS witH non 
valvular atrial fibrillation nvaf at a Private HoSPital in venezuela
Fernandez Y.1, Chiquinquira K.2, Garrido Lecca S.3
1Universidad Central de Venezuela Facultad de Medicina Escuela de Salud Publica, Caracas, 
Venezuela, 2Unesar Clinica Santa SofÃa, Caracas, Venezuela, 3Bristol-Myers Squibb, Lima, Peru
OBJECTIVES: Estimate direct medical costs of selected acute complications in 
patients with non-valvular atrial fibrillation (NVAF) at a private hospital “Clínica 
Santa Sofía” in Venezuela. METHODS: The hospital´s Medical Statistics Department 
was used to identify the study population. CIE-10 codes were used to identify 
patients with NVAF and select complications of AF. Complications of interest are: 
ischemic stroke, hemorrhagic stroke, systemic embolism, myocardial infarction, 
gastrointestinal hemorrhage and non-neurological hemorrhage. All cases from 2012 
-2013 meeting the inclusion criteria were reviewed. Patient level data from clinical 
charts was extracted to estimate resource utilization per patient per event. Costs 
were estimated using the hospital’s 2014 tariffs and expressed per patient in 2014 
Bolívares Fuertes (BsF). RESULTS: Mild and moderate ischemic stroke costs were 
estimated at BsF. 79,114 (SD 103,903), BsF 90,266 (SD 97,934). One case of mild, and 
one case of moderate ischemic stroke consumed high healthcare resources in this 
study population. Only one case of severe fatal ischemic stroke was identified and 
costs were estimated at BsF 14,143. No hemorragic stroke events were collected. 
Systemic embolism and myocardial infarction costs accounted for BsF 79,846 and 
BsF 36,332 (SD 13,865) respectively. Gastrointestinal hemorrhage was estimated at 
BsF 16,229 (SD 1,841) and only 1 event of non-neurological hemorrhage was col-
lected and costs estimated at BsF 8,864. CONCLUSIONS: Direct medical costs for 
NVAF patients at this private hospital increase as the severity of the event. High 
variability in costs was observed. Estimating these costs could help clinicians and 
decision makers a better understanding on the importance of preventing these 
complications with adequate NVAF treatment.
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Multiple sclerosis (MS) is an inflammatory demyelinating disease of central nerv-
ous system. It affects more than 1 million people in the world and the estimated 
prevalence in Colombia is of 4 to 5 per 100,000 inhabitants. It is a high cost disease 
and the drugs for its treatment were included to the benefit plan of health system 
since 2014.OBJECTIVES: Estimate the direct costs associated with the health care of 
patients with MS insured with a health manteinance organization (HMO) in Colombia 
during the period 2010-2014. METHODS: A retrospective cross-sectional study was 
conducted in a cohort of 163 patients distributed in 13 cities of the country and affili-
ated with a HMO in Colombia during January 2010 to December 2014. Demographic 
characteristics of the cohort are described and the average annual costs were esti-
mated by health service and patient. Costs were adjusted for inflation and expressed 
in 2014 US dollars. RESULTS: The prevalence of MS was 7.85 per 100,000 persons, the 
69.94% were female, the mean age was 40.91 years (SD 12.57 years), and cities with 
higher concentrations of patients were Bogotá (47%), Barranquilla (16%) and Medellin 
(9%). The average annual cost of care for the 163 patients was $ 2,663,500.79, mainly 
because drugs (85.39%), followed by diagnostic and therapeutic procedures (8.58%), 
magnetic resonance (1.21%), hospitalization (1.19%) and specialized consultations 
(0.92%). The average annual cost per patient was $ 21,303.43 (2010), $ 17,842.61 (2011), $ 
22,327.09 (2012), $ 22,662.90 (2013) and $ 20,205.28 (2014). CONCLUSIONS: The average 
annual cost per patient of MS in an insured population in Colombia corresponds to 
the annual premium per capita of 68 patients by 2014. Despite the change of technol-
ogy in the pharmacological treatment of these patients, there was not a significant 
increase in health care costs during the follow.
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OBJECTIVES: Pulmonary hypertension (PH) is classified into 5 groups. Group 3-PH 
is PH associated with lung diseases, such as chronic obstructive pulmonary dis-
ease (COPD), interstitial lung diseases (ILD), or those associated with sleep-related 
breathing disorders. We estimated the burden of Group 3 PH patients to US pay-
ers. METHODS: A 1:1 case-control study design using a large health insurance 
claims database was employed. Group 3-PH patients were identified using the fol-
lowing inclusion criteria: ≥ 2 medical claims for PH during July 1 2011 through June 
30 2012; at least one procedural claim for echocardiogram or right heart catheteriza-
tion, and at least one medical claim for COPD, ILD, breathing sleep disorders, alveolar 
hypoventilation disorder, chronic exposure to high altitude, or developmental lung 
diseases. Patients were excluded if they had a medical claim for left heart disease, 
pulmonary embolism, hematologic disorders, systemic disorders, metabolic disor-
ders or other categories as described in the 2013 classification of PH anytime during 
